

# Association Between Triglyceride Glucose Index and Infertility in Reproductive-Aged Women: A Cross-Sectional Study

Jiaru Zhuang<sup>1,2</sup>, Shan Wang<sup>1</sup>, Yuan Wang<sup>1</sup>, Renjing Hu<sup>1</sup>, Yibo Wu<sup>1</sup>

<sup>1</sup>Human Reproductive Medicine Center, Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu, 214026, People's Republic of China; <sup>2</sup>Department of Laboratory Medicine, Jiangnan University Medical Center, Wuxi, Jiangsu, 214000, People's Republic of China

Correspondence: Yibo Wu; Renjing Hu, Email 9862016107@jiangnan.edu.cn; weiweihuhu112@163.com

**Purpose:** In recent years, female infertility has become a research hotspot in the field of health management, and its cause may be related to insulin resistance (IR). We used a novel and practical IR indicator, the TyG index to explore its association with infertility.

**Patients and Methods:** We calculated the TyG index using data from adult women who participated in the National Health and Nutrition Examination Survey (NHANES) from 2013 to 2018. Then, we used multivariate logistic regression, smooth curve fitting, and subgroup analysis to examine the association between the TyG index and infertility in women.

**Results:** Logistic regression models showed a positive correlation between the TyG index and infertility, which remained significant even after adjusting for all confounders (OR=1.51, 95% CI: 1.14–2.00,  $p=0.005$ ). This association was consistent in all subgroups (age, education level, marital status, BMI, smoking, alcohol consumption, hypertension, diabetes, pelvic inflammatory disease/PID treatment, and menstrual regularity in the past 12 months) ( $p>0.05$  for all interactions). However, the diagnostic power of the TyG index for infertility was limited (AUC=0.56, 95% CI: 0.52–0.61).

**Conclusion:** The TyG index is positively correlated with infertility, but its diagnostic value is limited. Further research is needed on the TyG index as an early predictor of infertility.

**Keywords:** cross-sectional study, NHANES, infertility, insulin resistance, triglyceride glucose index, TyG

## Introduction

Infertility is the inability to conceive after more than 12 months of routine, unprotected sexual activity without the use of contraception.<sup>1,2</sup> In the United States, approximately 7% to 15.5% of women of childbearing age suffer from infertility.<sup>3</sup> The World Health Organization (WHO) has classified infertility as a major public health problem worldwide, affecting about 186 million people, including 15% of women of childbearing age.<sup>4–6</sup> In recent years, infertility has seriously threatened the progress of human civilization, and the US Centers for Disease Control and Prevention has proposed prioritizing the diagnosis and treatment of infertility.<sup>7</sup>

Epidemiological studies have shown that infertility is a fertility disorder caused by a variety of etiologies. Previous studies have shown that alcohol consumption, smoking, education level, and past medical history are associated with female infertility.<sup>8–10</sup> Metabolic abnormalities (such as metabolic syndrome; and obesity) are also prevalent in patients with infertility.<sup>11,12</sup> Studies have shown that insulin resistance (IR) is significantly associated with polycystic ovary syndrome (PCOS) and is a common cause of female infertility.<sup>13</sup> Currently, the “gold standard” for IR is glucose clamps. The steady-state model assessment (HOMA-IR) and quantitative insulin sensitivity check (QUIC) are alternatives to glucose clamp methods for assessing insulin and glucose levels to determine IR,<sup>14,15</sup> but they are expensive and difficult to perform in most underdeveloped regions, limiting the applicability of these indicators. Several recent studies have shown that the triglyceride-glucose (TyG) index, calculated using fasting triglyceride (TG) and glucose levels, is a simple

and reproducible marker for measuring insulin resistance (IR).<sup>16,17</sup> Given that the TyG index is an important indicator of insulin resistance, we hypothesize that it is associated with infertility.

A recent cross-sectional study explored the relationship between different insulin resistance substitutes and infertility in women of childbearing age.<sup>18</sup> However, our study aims to explore a potential association between a single TyG index and female infertility using a nationally representative sample of women of childbearing age from the National Health and Nutrition Examination Survey (NHANES). This may provide a new perspective in the field of female reproductive health management.

## Material and Methods

### Data Source

Data for this study are from the National Health and Nutrition Survey (NHANES), a national program that assesses nutrition and health in the United States, published by the National Center for Health Statistics (NCHS). The survey was conducted using a complex multi-stage probabilistic design to produce a nationally representative sample of non-institutionalized Americans. Participants conducted a family interview to collect data on their health, socioeconomic status, and other factors. A mobile examination facility served as the setting for physical and laboratory examinations.

Study procedures are reviewed and standardized annually by the National Center for Health Statistics (NCHS) Ethics Review Committee (NCHS IRB/ERB Protocol #2011-17). All participants provided informed consent before data collection. For more detailed information, please refer to <http://www.cdc.gov/nchs/nhanes/index.htm>. As the data in the NHANES database are publicly available, the approval statement and informed consent requirements are waived for this study. This cross-sectional study followed the criteria for enhanced epidemiological observational reporting.<sup>19</sup>

### Study Population

Infertility-related health problems were only included in the NHANES cycle from 2013 to 2018. Therefore, we used this time period as our data. In our analysis, we included participants with comprehensive information on infertility and TyG index. Initially, a total of 29,400 participants were included. After excluding male participants (n=14,452), participants lacking data on TyG index (n=10,433), fertility information (n=2120), and participants older than 45 years or younger than 18 years (n=839), our final analysis included 1556 eligible participants (Figure 1).

### Triglyceride Glucose Index


Serum levels were measured for participants who were examined in the morning session only. The distribution of serum triglycerides should be estimated only for participants aged 12 and above who fasted for at least 8.5 hours, but less than 24 hours. Fasting total triglyceride concentration was determined using an automated biochemistry analyzer. The TyG index was calculated using the formula:  $\text{Ln}[\text{fasting triglycerides (mg/dL)} \times \text{fasting plasma glucose (mg/dL)} / 2]$ .<sup>20</sup>

### Infertility

Self-reported infertility data were obtained from the NHANES Reproductive Health Questionnaire (RHQ). The presence of infertility was assessed based on the following question: "Have you ever tried to conceive for at least a year without becoming pregnant?" Women who answered "yes" were considered infertile, while those who answered "no" were considered to be childbearing.

### Covariables

Based on the available literature,<sup>21–23</sup> this study included a variety of covariates that may affect the relationship between the TyG index and the risk of developing infertility. Variables considered included age, Race, education level, marital status, poverty income ratio (PIR), body mass index (BMI), hypertension, diabetes, smoking status, alcohol consumption, regular menstrual periods in the past 12 months (yes/no), previous treatment for pelvic infection/pelvic inflammatory disease (yes/no), previous use of birth control pills (yes/no), total cholesterol (TC), fasting triglycerides (TG), fasting



**Figure 1** Flow chart of the inclusion and exclusion of study participants.

plasma glucose (FPG), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and glycosylated hemoglobin (HbA1c).

## Statistical Analysis

All statistical analyses for this study were performed in accordance with Centers for Disease Control and Prevention (CDC) guidelines. Dividing the 2-year weights for each cycle by 2, we arrive at the new sample weights for the combined survey periods.

In descriptive analysis, the two comparison groups identified based on infertility status were assessed using either a weighted Student-*t*-test (for continuous variables) or a weighted chi-square test (for categorical data). Categorical parameters were expressed as proportions, while continuous variables were summarized as means and standard deviations. A multivariate logistic regression model using the NHANES complex sampling design (sampling weights) was used to investigate the association between TyG index and infertility expressing the relationship with OR values and 95%

confidence intervals (95% CI). In the analysis we developed three models, Model I crude model without any adjustment, minimum adjusted (Model II) adjusted age and race and fully adjusted model (Model III) adjusted for all covariate we further assessed the differences in the risk of infertility between the different TyG index tertile groups using lowest tertile group as reference one. Subgroup analysis was used to study the relationship between TyG index and infertility in age, education level, marital status, BMI, smoking, alcohol consumption, hypertension, diabetes mellitus, regular menstruation in the past 12 months, and pelvic inflammatory disease/PID treatment. The interaction test and stratified analysis was used to study whether the relationship between TyG index and infertility was consistent among each subgroup. The method of smooth curve fitting was used to explore the nonlinear relationship between the TyG index and infertility. To determine the diagnostic validity of the TyG index for infertility, the receiver operating characteristic (ROC) curve was used, and the area under the ROC curve (AUC) was calculated to quantify its screening value. All analyses were performed using Empower software and R version 4.3.2. A p-value of  $<0.05$  was considered significant.

## Results

### Baseline Characteristics

A total of 1556 participants aged 18 to 45 years were included, of whom 169 were infertility patients. The characteristics of the study participants according to their infertility status are shown in Table 1. Self-reported infertility was more prevalent in women who were older, married/cohabiting, had a higher BMI, smoked, drank alcohol, had high blood pressure and diabetes, had received pelvic inflammatory disease/PID treatment, and had irregular menstrual periods. In addition, self-reported infertility was also more prevalent among women with a higher TyG index, averaging  $8.34 \pm 0.63$ .

### Association Between TyG Index and Infertility

The relationship between the TyG index and infertility is shown in Table 2. Our findings suggest that a higher TyG index is associated with a higher risk of infertility. Both the crude model and the minimum/fully adjusted model showed a positive correlation between the TyG index and infertility. In the fully adjusted model, participants had a 51% increased risk of infertility for each unit increase in the TyG index (OR=1.51, 95% CI:1.14–2.00). This association remained statistically significant after converting the TyG index from a continuous variable to a categorical variable (tertiles). Individuals in the highest TyG index had a 72% increased risk of infertility compared to participants in the lowest TyG

**Table 1** Baseline Characteristics of Participants

Characteristic	Total	Control	Infertility	P-value
	N=1556	N=1387	N=169	
Age, (years)	31.40 $\pm$ 8.07	30.92 $\pm$ 8.03	34.88 $\pm$ 7.51	<0.001
Poverty income ratio (PIR)	2.56 $\pm$ 1.64	2.55 $\pm$ 1.64	2.69 $\pm$ 1.66	0.294
Fasting Glucose (mg/dl)	98.33 $\pm$ 22.05	97.77 $\pm$ 20.09	102.40 $\pm$ 32.63	0.007
Total Cholesterol (mg/dl)	179.37 $\pm$ 35.88	179.25 $\pm$ 35.73	180.25 $\pm$ 36.97	0.718
HDL Cholesterol (mg/dl)	57.76 $\pm$ 15.97	58.27 $\pm$ 15.99	54.04 $\pm$ 15.35	<0.001
LDL cholesterol (mg/dl)	103.47 $\pm$ 30.50	103.04 $\pm$ 30.37	106.65 $\pm$ 31.27	0.123
Triglyceride (mg/dl)	91.30 $\pm$ 62.01	90.21 $\pm$ 59.94	99.22 $\pm$ 74.88	0.061
HbA1c (%)	5.34 $\pm$ 0.67	5.31 $\pm$ 0.63	5.51 $\pm$ 0.94	<0.001
TyG	8.22 $\pm$ 0.63	8.21 $\pm$ 0.63	8.34 $\pm$ 0.63	0.005
Race, (%)				0.486
Mexican American	11.93	12.26	9.56	
Other Hispanic	7.89	8.03	6.93	
Non-Hispanic white	55.90	55.07	61.89	
Non-Hispanic black	13.16	13.26	12.41	
Other Races	11.12	11.38	9.21	

(Continued)

**Table 1** (Continued).

Characteristic	Total	Control	Infertility	P-value
	N=1556	N=1387	N=169	
Education level (%)				0.253
Less than high school	12.04	11.82	13.57	
High school	20.72	21.38	16.27	
Above high school	67.23	66.80	70.17	
Marital status				<0.001
Married or living with partner	60.48	57.47	80.92	
Living alone	39.52	42.53	19.08	
BMI (kg/m <sup>2</sup> )				<0.001
<25	36.57	38.18	24.95	
≥25	63.43	61.82	75.05	
Smoking status (%)				0.027
Yes	31.61	30.64	38.59	
No	68.39	69.36	61.41	
Alcohol drinking status (%)				0.007
Yes	7.70	6.92	12.80	
No	92.30	93.08	87.20	
Hypertension (%)				<0.001
Yes	14.10	12.55	25.35	
No	85.90	87.45	74.65	
Diabetes (%)				<0.001
Yes	4.78	3.91	11.03	
No	95.22	96.09	88.97	
Had regular periods in past 12 months (%)				<0.001
Yes	89.33	90.33	82.14	
No	10.67	9.67	17.86	
Ever treated for a pelvic infection/PID (%)				0.003
Yes	4.25	3.69	8.28	
No	95.75	96.31	91.72	
Ever taken birth control pills (%)				0.140
Yes	73.18	72.56	77.65	
No	26.82	27.44	22.35	

**Table 2** Associations Between TyG Index and the Risk of Infertility

TyG Index	Infertility [OR (95% CI)]
Crude model (model 1)	
Continuous	1.41 (1.12, 1.79)
Categories	
Quartile 1	Reference
Quartile 2	1.51 (0.99, 2.29)
Quartile 3	1.65 (1.10, 2.49)
Minimally adjusted model (model 2)	
Continuous	1.45 (1.14, 1.85)
Categories	
Quartile 1	Reference
Quartile 2	1.52 (1.00, 2.32)
Quartile 3	1.72 (1.13, 2.63)

(Continued)

**Table 2** (Continued).

TyG Index	Infertility [OR (95% CI)]
Fully adjusted model (model 3)	
Continuous	1.51 (1.14, 2.00)
Categories	
Quartile 1	Reference
Quartile 2	1.78 (1.12, 2.83)
Quartile 3	1.72 (1.05, 2.84)

**Notes:** In sensitivity analysis, the TyG index was converted from a continuous variable to a categorical variable (tertiles). Model 1, No covariates were adjusted; Model 2, Adjusted for age and race; Model 3, Adjusted for age, ratio of family income to poverty, race, education level, marital status, smoked at least 100 cigarettes, had at least 12 alcohol drinks/1 year, ever treated for a pelvic infection/PID, ever taken birth control pills, had regular periods in past 12 months.

**Abbreviations:** 95% CI, 95% Confidence Interval; OR, Odds Ratio.


index (OR=1.72, 95% CI:1.05–2.84) (Table 2). Additionally, we further investigated the relationship between the TyG index and the risk of infertility using smooth curve fitting, which showed a positive nonlinear relationship (Figure 2).

## Subgroup Analyses

We conducted subgroup analyses to assess the stability of the relationship between TyG index and infertility across various factors. We found that in participants aged  $\geq 35$  years, each unit increase in TyG index was associated with an 81% higher likelihood of infertility (OR:1.81, 95% CI:1.10–2.99). As shown in Table 3, factors such as age, education level, marital status, BMI, smoking, alcohol consumption, hypertension, diabetes, pelvic inflammatory disease/PID treatment, and menstrual regularity in the past 12 months did not significantly affect the positive correlation between TyG and infertility (all  $p > 0.05$ ).

## Diagnostic Efficacy of TyG Index for Infertility

The diagnostic validity of the TyG index was analyzed using the receiver operating characteristic (ROC) curve (Figure 3). The cut-off value for the diagnosis of infertility was 7.725 (AUC=0.56, 95% CI:0.52–0.61, sensitivity=89%, specificity=24.2%). AUC values above 0.5 are considered to have diagnostic utility.



**Figure 2** Smoothing curve fitting of TyG index and infertility.

**Table 3** Subgroups Analyses of the effect of TyG Index on Infertility


Subgroup	Infertility [OR (95% CI)]	P for Interaction
Age		0.056
<35	0.96 (0.62, 1.47)	
≥35	1.81 (1.10, 2.99)	
Marital status		0.843
Married or living with partner	1.04 (0.74, 1.46)	
Living alone	1.11 (0.65, 1.90)	
Education level		0.633
Less than high school	1.19 (0.56, 2.53)	
High school	1.08 (0.51, 2.28)	
Above high school	0.98 (0.68, 1.41)	
BMI		0.837
<25	1.17 (0.57, 2.40)	
≥25	1.08 (0.78, 1.49)	
Smoking status		0.820
Yes	1.27 (0.77, 2.10)	
No	1.18 (0.78, 1.77)	
Alcohol drinking status		0.765
Yes	0.98 (0.32, 3.04)	
No	1.18 (0.84, 1.65)	
Diabetes		0.333
Yes	1.75 (0.68, 4.54)	
No	1.07 (0.78, 1.48)	
Hypertension		0.210
Yes	0.79 (0.46, 1.36)	
No	1.19 (0.84, 1.68)	
Had regular periods in past 12 months		0.113
Yes	1.14(0.82,1.59)	
No	3.07(0.91,10.39)	
Ever treated for a pelvic infection/PID		0.110
Yes	3.04(0.85,10.88)	
No	1.09(0.79,1.51)	

## Discussion

The study, which evaluated the relationship between TyG index and infertility through the NHANES database, showed that TyG index levels were significantly higher in the infertility group than in the non-infertility group. Smooth curve fitting was used to demonstrate a positive linear relationship between TyG index and infertility. Importantly, there was still a statistically significant correlation between TyG index and infertility after adjusting for multiple confounders in the fully adjusted model, suggesting that TyG index may be used as a simple indicator to assess infertility in the future. However, the diagnostic validity of the TyG index for infertility is limited, and further research is needed to fully explore its potential as an early risk predictor of infertility.

The TyG index, consisting of triglycerides and fasting blood glucose, has been shown to be a good predictor of insulin resistance. Infertility and insulin resistance (IR) have been found to be closely related (IR),<sup>13</sup> with a significantly increased risk of infertility in young adults and non-diabetic individuals as insulin resistance increases.<sup>24,25</sup> In addition, PCOS affects 5% to 15% of women of childbearing age worldwide and is a major cause of infertility. Its occurrence is associated with insulin resistance and glucose tolerance disorders.<sup>26</sup> In this setting, IR is generally considered to be the primary pathophysiological mechanism leading to infertility in PCOS.<sup>27,28</sup> At the same time, IR also has a negative impact on assisted reproductive technology (ART). Song et al<sup>29</sup> conducted a retrospective study of 329 women undergoing IVF, and the results showed a significant reduction in clinical pregnancy rates in participants with higher HOMA-IR and BMI. Another prospective cohort study from China found that the proportion of eggs and embryo quality decreased in infertility patients without PCOS.<sup>30</sup>





**Figure 3** ROC curve of the TyG index used to diagnose infertility.

In our study, an elevated TyG index was observed to be associated with a higher prevalence of infertility in participants over 35 years of age. In Integral Chinese, most women aged 36 years or older had a reduced number of oocytes and an increased risk of infertility.<sup>31</sup> In the current study, we confirmed through interaction tests that age had no significant effect on the outcome of the correlation. We believe a plausible explanation for this is that an increase in the TyG index may be associated with a greater degree of insulin resistance (IR), a higher prevalence of IR-related comorbidities, and ultimately an increased risk of infertility due to the increase in comorbidities.

The details of the mechanism that explains the relationship between the TyG index and infertility still need to be further explored, and there are several possible explanations. First, insulin resistance (IR) may affect oocyte quality by decreasing mitochondrial function. Studies have shown that mitochondrial dysfunction can disrupt the insulin signaling pathway and impair glucose metabolism.<sup>32</sup> Secondly, IR has a regulatory effect on oocyte energy metabolism. Glucose transporter (GLUT4) is key to intracellular energy supply, and the decrease in GLUT4 expression in PCOS patients with IR affects the uptake and utilization of glucose by ovarian granulosa cells. This ultimately reduces oocyte quality and affecting reproductive function.<sup>33</sup> Additionally, hyperandrogenism is thought to play an important role in PCOS leading to infertility. Systemic hyperandrogenism perpetuates abnormal glucose/insulin metabolism, decreases hepatic sex hormone-binding globulin production, alters hypothalamic-pituitary-ovarian (HPO) signaling, and dysregulates growth factor activity (IGF1, GDF9, activin, albumin, etc.), all of which exacerbate the sensitive feedback system of the reproductive cycle.<sup>34,35</sup> Studies have also found improved fertility in women with hyperandrogenic PCOS treated with androgen blockers such as fluticasone.<sup>36</sup> Finally, in addition to affecting oocyte quality, IR also affects endometrial tolerance through multiple pathways, including chronic inflammation. This, in turn, affects female fertility.<sup>37–39</sup>

A recent cross-sectional study found that the TyG-BMI index had a higher predictive power than the TyG index in assessing infertility in women of childbearing age.<sup>18</sup> However, our findings suggest that the TyG index has limited ability to diagnose infertility (AUC=0.56), which is similar to our findings. This may be because the TyG-BMI index contains not only markers of insulin resistance, but also BMI indicators to measure obesity. The combination of the two will inevitably improve the predictive power. However, our study only explored the association of a single index with infertility in women of childbearing age. In the future, it is necessary to further explore the joint index to evaluate its potential for prediction.

The advantage of our study is the use of a complex multi-stage probabilistic sampling design, which increases the reliability and representativeness of our research. Our study also had limitations. First of all, due to the cross-sectional design of the analysis, we were unable to determine the causal relationship between TyG index and infertility. In addition, due to limitations in the NHANES database, the definition of female infertility outcome variables is based on self-report and, while a useful measure, may be less accurate in some cases. For example, women who are planning to become pregnant for less than a year but have already



sought medical attention may be included, as well as other definitions of infertility (ie, medical records or time spent pregnant) that may influence the probability of developing infertility.<sup>40,41</sup> Further research needs to consider the implications of different definitions. Finally, while we adjust for some confounders, it is not possible to completely rule out the influence of other possible confounders. This study confirms the association between the TyG index and infertility, despite these limitations.

## Conclusion

Current research shows that the TyG index of adult women in the United States is positively correlated with infertility. However, the TyG index has limited diagnostic validity for infertility. Further research is needed to fully explore the potential of the TyG index as a predictor of infertility.

## Data Sharing Statement

Publicly available datasets were analyzed in this study. This data can be found here: <https://wwwn.cdc.gov/nchs/nhanes>.

## Acknowledgments

The authors express their gratitude towards the participants and staff of the NHANES database for their noteworthy contributions.

## Funding

This study was supported by the Wuxi Taihu Lake Talent Plan, Supports for Leading Talents in Medical and Health Profession (Mading academician, 4532001THMD), and grant from the Fund of Wuxi Health Commission(M202214).

## Disclosure

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

## References

1. Broughton DE, Moley KH. Obesity and female infertility: potential mediators of obesity's impact. *Fertil Steril*. 2017;107(4):840–847. doi:10.1016/j.fertnstert.2017.01.017
2. Caballero B. Humans against obesity: who will win? *Adv Nutr*. 2019;10:S4–S9. doi:10.1093/advances/nmy055
3. Ding C, Shi Y, Li J, et al. Association of weight-adjusted-waist index with all-cause and cardiovascular mortality in China: a prospective cohort study. *Nutr Metab Cardiovasc Dis*. 2022;32(5):1210–1217. doi:10.1016/j.numecd.2022.01.033
4. Buzadzic B, Vucetic M, Jankovic A, et al. New insights into male (in)fertility: the importance of NO. *Br J Pharmacol*. 2014;172(6):1455–1467. doi:10.1111/bph.12675
5. Palermo GD, O'Neill CL, Chow S, et al. Intracytoplasmic sperm injection: state of the art in humans. *Reproduction*. 2017;154(6):F93–F110. doi:10.1530/rep-17-0374
6. Yokota R, Okuhara T, Ueno H, Okada H, Furukawa E, Kiuchi T. Online Japanese-language information on lifestyle factors associated with reduced fertility: content analysis. *J Med Int Res*. 2020;22:8 doi:10.2196/19777
7. Macaluso M, Wright-Schnapp TJ, Chandra A, et al. A public health focus on infertility prevention, detection, and management. *Fertil Steril*. 2010;93(1):16 e1–10. doi:10.1016/j.fertnstert.2008.09.046
8. Zhou Z, Zheng D, Wu H, et al. Epidemiology of infertility in China: a population-based study. *BJOG*. 2018;125(4):432–441. doi:10.1111/1471-0528.14966
9. Finelli R, Mottola F, Agarwal A. Impact of alcohol consumption on male fertility potential: a narrative review. *Int J Environ Res Public Health*. 2021;19:1 doi:10.3390/ijerph19010328
10. Wesselink AK, Hatch EE, Rothman KJ, Mikkelsen EM, Aschengrau A, Wise LA. Prospective study of cigarette smoking and fecundability. *Hum Reprod*. 2019;34(3):558–567. doi:10.1093/humrep/dey372
11. Marchiani S, Tamburrino L, McPherson N, Baldi E. Editorial: the role of obesity and metabolic syndrome in couple infertility. *Front Endocrinol*. 2021;12. doi:10.3389/fendo.2021.784716
12. Silvestris E, de Pergola G, Rosania R, Loverro G. Obesity as disruptor of the female fertility. *Reprod Biol Endocrinol*. 2018;16(1):22. doi:10.1186/s12958-018-0336-z
13. Vatie C, Christin-Maitre S, Vigouroux C. Role of insulin resistance on fertility - Focus on polycystic ovary syndrome. *Ann Endocrinol*. 2022;83(3):199–202. doi:10.1016/j.ando.2022.04.004
14. Muniyappa R, Lee S, Chen H, Quon MJ. Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage. *Am J Physiol Endocrinol Metab*. 2008;294(1):E15–26. doi:10.1152/ajpendo.00645.2007
15. Matthews HJ, Rudenski AS, Naylor BA, Treacher DF, Turner RC. homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. *Diabetologia*. 1985;28(7):412–419. doi:10.1007/BF00280883

16. Mazidi M, Kengne AP, Katsiki N, Mikhailidis DP, Banach M. Lipid accumulation product and triglycerides/glucose index are useful predictors of insulin resistance. *J Diabetes Complications*. 2018;32(3):266–270. doi:10.1016/j.jdiacomp.2017.10.007
17. Kang B, Yang Y, Lee EY, et al. Triglycerides/glucose index is a useful surrogate marker of insulin resistance among adolescents. *Int J Obes*. 2017;41(5):789–792. doi:10.1038/ijo.2017.14
18. Xia W, Cai Y, Zhang S, Wu S. Association between different insulin resistance surrogates and infertility in reproductive-aged females. *BMC Public Health*. 2023;23:1 doi:10.1186/s12889-023-16813-2
19. von Elm E, Altman DG, Egger M, et al. The Strengthening of Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *Lancet*. 2007;370(9596):1453–1457. doi:10.1016/S0140-6736(07)61602-X
20. Simental-Mendia LE, Rodriguez-Moran M, Guerrero-Romero F. The product of fasting glucose and triglycerides as surrogate for identifying insulin resistance in apparently healthy subjects. *Metab Syndr Relat Disord*. 2008;6(4):299–304. doi:10.1089/met.2008.0034
21. Wen Z, Li X. Association between weight-adjusted-waist index and female infertility: a population-based study. *Front Endocrinol*. 2023;14:1175394. doi:10.3389/fendo.2023.1175394
22. Zeng Y, Yin L, Yin X, Zhao D. Association of triglyceride-glucose index levels with gestational diabetes mellitus in the US pregnant women: a cross-sectional study. *Front Endocrinol*. 2023;14:1241372. doi:10.3389/fendo.2023.1241372
23. Yin Y-H, Zhou S-Y, D-F L, et al. Higher waist circumference is associated with increased likelihood of female infertility: NHANES 2017–2020 results. *Front Endocrinol*. 2023;14. doi:10.3389/fendo.2023.1216413
24. Huang-Doran I, Kinzer AB, Jimenez-Linan M, et al. Ovarian hyperandrogenism and response to gonadotropin-releasing hormone analogues in primary severe insulin resistance. *J Clin Endocrinol Metab*. 2021;106(8):2367–2383. doi:10.1210/clinem/dgab275
25. Ezech U, Pisarska MD, Azziz R. Association of severity of menstrual dysfunction with hyperinsulinemia and dysglycemia in polycystic ovary syndrome. *Hum Reprod*. 2022;37(3):553–564. doi:10.1093/humrep/deac001
26. Osibogun O, Ogunmoroti O, Michos ED. Polycystic ovary syndrome and cardiometabolic risk: opportunities for cardiovascular disease prevention. *Trends Cardiovasc Med*. 2020;30(7):399–404. doi:10.1016/j.tcm.2019.08.010
27. Diamanti-Kandarakis E, Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. *Endocr Rev*. 2012;33(6):981–1030. doi:10.1210/er.2011-1034
28. Ding H, Zhang J, Zhang F, et al. Resistance to the insulin and elevated level of androgen: a major cause of polycystic ovary syndrome. *Front Endocrinol*. 2021;12:741764. doi:10.3389/fendo.2021.741764
29. Song H, Yu Z, Li P, Wang Y, Shi Y. HOMA-IR for predicting clinical pregnancy rate during IVF. *Gynecol Endocrinol*. 2022;38(1):33–38. doi:10.1080/09513590.2021.1952976
30. Wang H, Zhang Y, Fang X, Kwak-Kim J, Wu L. Insulin resistance adversely affect IVF outcomes in lean women without PCOS. *Front Endocrinol*. 2021;12:734638. doi:10.3389/fendo.2021.734638
31. Mihalas BP, Pieper GH, Aboelenain M, et al. Age-dependent loss of cohesion protection in human oocytes. *Curr Biol*. 2024;34(1):117–131 e5. doi:10.1016/j.cub.2023.11.061
32. Zeber-Lubecka N, Ciebiera M, Hennig EE. Polycystic ovary syndrome and oxidative stress-from bench to bedside. *Int J Mol Sci*. 2023;24:18 doi:10.3390/ijms241814126
33. Zhu Q, Zuo R, He Y, et al. Local regeneration of cortisol by 11beta-HSD1 contributes to insulin resistance of the granulosa cells in PCOS. *J Clin Endocrinol Metab*. 2016;101(5):2168–2177. doi:10.1210/jc.2015-3899
34. Franks S. Animal models and the developmental origins of polycystic ovary syndrome: increasing evidence for the role of androgens in programming reproductive and metabolic dysfunction. *Endocrinology*. 2012;153(6):2536–2538. doi:10.1210/en.2012-1366
35. Walters KA. Role of androgens in normal and pathological ovarian function. *Reproduction*. 2015;149(4):R193–218. doi:10.1530/REP-14-0517
36. Naamneh Elzenaty R, du Toit T, Fluck CE. Basics of androgen synthesis and action. *Best Pract Res Clin Endocrinol Metab*. 2022;36(4):101665. doi:10.1016/j.beem.2022.101665
37. Mumford SL, Legro RS, Diamond MP, et al. Baseline AMH level associated with ovulation following ovulation induction in women with polycystic ovary syndrome. *J Clin Endocrinol Metab*. 2016;101(9):3288–3296. doi:10.1210/jc.2016-1340
38. Chappell NR, Barsky M, Shah J, et al. Embryos from polycystic ovary syndrome patients with hyperandrogenemia reach morula stage faster than controls. *F S Rep*. 2020;1(2):125–132. doi:10.1016/j.xfre.2020.05.006
39. Sha T, Wang X, Cheng W, Yan Y. A meta-analysis of pregnancy-related outcomes and complications in women with polycystic ovary syndrome undergoing IVF. *Reprod Biomed Online*. 2019;39(2):281–293. doi:10.1016/j.rbmo.2019.03.203
40. Wang H, Zhang J, Pu Y, et al. Comparison of different insulin resistance surrogates to predict hyperuricemia among U.S. non-diabetic adults. *Front Endocrinol*. 2022;13:1028167. doi:10.3389/fendo.2022.1028167
41. Larsen U. Research on infertility: which definition should we use? *Fertil Steril*. 2005;83(4):846–852. doi:10.1016/j.fertnstert.2004.11.033

## International Journal of Women's Health

Dovepress

## Publish your work in this journal

The International Journal of Women's Health is an international, peer-reviewed open-access journal publishing original research, reports, editorials, reviews and commentaries on all aspects of women's healthcare including gynecology, obstetrics, and breast cancer. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/international-journal-of-womens-health-journal>